Senco Gold Q4 Profit Surges 151 to 157 Crore on Soaring Gold Prices and Wedding Demand Charter Communications and Liberty Broadband Reach Revised AllStock Acquisition Agreement Mortgage Rates Mixed as of May 24 2026 30Year Fixed Dips 15Year Rises China Urges APEC Cooperation Amid Ministers Absence Due to Urgent Official Business Humana Eyes MultiYear Margin and Returns Recovery Signaling Potential Strategic Turnaround Consumer Sentiment Drops to Fresh Record Low in May on Iran Conflict and Oil Price Concerns CGON Q1 2026 Earnings EPS Misses Estimates as ClinicalStage Biotech Continues RD Investment Golar LNG Ltd GLNG Q1 2026 Earnings EPS Beats Estimates by 245 Revenue Not Disclosed MetLife MET Q1 2026 Earnings Earnings Beat Driven by Strong Underwriting and Investment Performance BOX Q1 2026 Earnings Strong EPS Beat Drives Positive Market Reaction ALGS Q1 2026 Earnings NarrowerthanExpected Loss as Aligos Therapeutics Advances Pipeline Live Oak Bancshares LOB Q1 2026 Earnings Strong EPS Beat as Net Interest Margins Hold Steady CoreCivic Inc CXW Edges Lower Testing Key Support Levels Amid Modest Decline GBank Financial Holdings Inc GBFH Holds Near Support Amid Quiet Session MFS Multimarket Income Trust MMT Holds Steady at 449 as Trading Range Narrows Biogen BIIB Gains 130 as Sector Support Holds Key Resistance in Focus Newegg Commerce Inc NEGG Surges 316 as Momentum Builds Above Support Japans Beef Bowl Chains Face Supply Strain as US Meat Prices Surge BiomX Inc PHGE Q4 2025 Earnings EPS Misses by Wide Margin No Revenue Stock Declines RingCentral RNG Surges 313 as Shares Approach Key Resistance GENI Q1 2026 Earnings Widened Loss Surprises Market Yet Stock Rallies AXP Q1 2026 Earnings EPS Beat of 533 Highlights Resilient Spending BGS Q1 2026 Earnings EPS Surpasses Expectations Despite Weak Stock Reaction UBFO Q4 2025 Earnings Solid EPS of 019 Reported Shares Remain Flat LXP Industrial Trust Q1 2026 Earnings EPS Miss Reflects Challenging Industrial Market Conditions Soleno Therapeutics SLNO Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Refocuses on Clinical Milestones GRNT Q1 2026 Earnings Sharp EPS Miss Weighs on Investor Sentiment